 | This article needs additional citations for verification. (February 2009) |
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology, Pharmaceutical Company |
| Founded | 1993 |
| Defunct | N/A |
| Headquarters | Cambridge, MA, United States |
Key people | Christophe Bianchi, President |
| Products | Velcade (bortezomib) for injection |
Number of employees | 1200 (approx.) |
| Parent | Takeda Pharmaceutical Company |
| Website | www |
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.
Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease,[1] although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.[1]
It is particularly known for bringing bortezomib (marketed as Velcade) through clinical trials to approval for treatment of patients with multiple myeloma by the U.S. FDA, but has a growing clinical development pipeline of other product candidates.
On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal worth $8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger as a wholly owned subsidiary Millennium: The Takeda Oncology Company - with the name being simplified to Takeda Oncology in 2013.
- ^ a b Pollack, Andrew (2005-06-29). "Shift Seen Atop Takeda Oncology". New York Times. Retrieved 2008-02-23.